Improving Adherence With Amlodipine/Atorvastatin Therapy: IMPACT Study
Article first published online: 29 JUN 2011
© 2011 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 13, Issue 8, pages 598–604, August 2011
How to Cite
Oliver, S., Jones, J., Leonard, D., Crabbe, A. and Delkhah, Y. (2011), Improving Adherence With Amlodipine/Atorvastatin Therapy: IMPACT Study. The Journal of Clinical Hypertension, 13: 598–604. doi: 10.1111/j.1751-7176.2011.00478.x
- Issue published online: 1 AUG 2011
- Article first published online: 29 JUN 2011
- Manuscript received November 28, 2010; Revised: February 28, 2011; Accepted: March 4, 2011
Vol. 13, Issue 10, 784, Article first published online: 26 SEP 2011
J Clin Hypertens (Greenwich). 2011;13:598–604.©2011 Wiley Periodicals, Inc.
Hypertension is prevalent in the United States and remains uncontrolled. The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals. The study was conducted in middle-aged, indigent, African Americans who had high-risk, resistant hypertension and dyslipidemia. Patients were randomly assigned to either the home and clinic BP group or usual care group and were followed for 6 months. The average BPs for each group were compared and used to titrate the study drug appropriately. Both groups achieved significant declines in BP, total cholesterol, and low-density lipoprotein (LDL) (P<.0001). These findings demonstrate that BP control could be achieved at a rate of 43.5% compared with the 2004 national control rate of 35%. The LDL control rate was also improved. Cardiovascular risk reduction has been proven to be achieved through managing lipids and BP. This trial demonstrates that these goals can be achieved similar to other groups in indigent African Americans with high-risk hypertension and dyslipidemia.